The antiplatelet aggregation effects of aspirin suppositories

Cerebrovascular Diseases

Volumn 16, Issue 1, 2003, Pages 31-35

  Nakayasu, Hiroyuki ^a   Maeda, Masanobu ^a   Soda, Takao ^a   Iijima, Kenji ^b   Ishimoto, Manabu ^b   Ieiri, Ichiro ^b   Tabuchi, Fumie ^b   Otsubo, Kenji ^b   Nakashima, Kenji ^a  

^a TOTTORI UNIVERSITY   (Japan)

^b TOTTORI UNIVERSITY HOSPITAL   (Japan)

Author keywords

Aspirin concentration; Cerebral infarction; Ischemic stroke; Treatment

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ANTITHROMBOCYTIC AGENT; COLLAGEN; WITEPSOL;

ACUTE DISEASE; ADULT; ARTICLE; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PRIORITY JOURNAL; SUPPOSITORY; THROMBOCYTE AGGREGATION INHIBITION;

ADENOSINE DIPHOSPHATE; ADULT; ASPIRIN; COLLAGEN; FEMALE; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HUMANS; MALE; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; SEX CHARACTERISTICS; SUPPOSITORIES;

EID: 0037641171     PISSN: 10159770     EISSN: None     Source Type: Journal    
DOI: 10.1159/000070112     Document Type: Article

References (14)

1. CAST: Randomized placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. CAST (Chinese Acute Stroke Trials) Collaborative Group. Lancet 1997;349:1641-1649.
2. The international stroke trial (IST): A randomized trial of aspirin, subcutaneous heparin, both, or neither among 19,435 patients with acute ischaemic stroke. International Stroke Trial Collaborative Group. Lancet 1997;349:1569-1581.
3. Schöndorf TH: The effect of acetylsalicylic-lysine on platelet function. Klin Wochenschr 1975;53:1125-1129.
4. Hanaue H, Ogoshi K, Makuuchi H, Mitomi T, Kurosawa T, Nemoto A, Kitano Y, Miyakawa S, Yamoto H, Asagoe T, Shikata J: Postoperative intravenous administration of lysine acetylsalicylate: Effect on pain relief and platelet function. Clin Ther 1987;9:159-166.
5. Needs CJ, Brooks PM: Clinical pharmacokinetics of the salicylates. Clin Pharmacokinet 1985;10:164-177.
6. Pedersen AK, FitzGerald GA: Preparation and analysis of deuterium-labeled aspirin: Application to pharmacokinetic studies. J Pharm Sci 1985;74:188-192.
7. Jimenez AH, Stubbs ME, Tofler GH, Winther K, Williams GH, Muller, JE: Rapidity and duration of platelet suppression by enteric-coated aspirin in healthy young men. Am J Cardiol 1992;69:258-262.
8. Mousa SA, Forsythe MS, Bozarth JM, Reilly TM: Effect of single oral dose of aspirin on human platelet functions and plasma plasminogen activator inhibitor-1. Cardiology 1993;83:367-373.
9. Taylor RR, Sturm M, Vandongen R, Strophair J, Beilin LJ: Whole blood platelet aggregation is not affected by cigarette smoking but is sex-related. Clin Exp Pharmacol Physiol 1987;14:665-671.
10. Zwierzina WD, Kunz F, Kogelnig R, Herold M: Sex-related differences in platelet aggregation in native whole blood. Thromb Res 1987;48:161-171.
11. Spranger M, Aspey BS, Harrison MJG: Sex difference in antithrombotic effect of aspirin. Stroke 1989;20:34-37.
12. Sivenius J, Laakso M, Penttilä IM, Smets P, Lowenthal A, Riekkinen PJ: The European Stroke Prevention Study: Results according to sex. Neurology 1991;41:1189-1192.
13. Antiplatelet Trialists' Collaboration: Collaborative overview of randomised trials of anti-platelet therapy. 1. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994;308:81-106.
14. Walter E, Zimmermann R, Siess R, Staiger C, Weber E: Biphasic initial phase of platelet aggregation inhibition after oral aspirin. Artery 1980;8:501-506.